Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment

Travassos, Priscila Nunes Costa; Silva, Paulo Goberlânio de Barros; Freitas, Milena Oliveira; Braga, Marcus Davis Machado; Duarte, Fernando Barroso; Maia, Jéssica Karen de Oliveira; Pitombeira, Helena; Sousa, Jacqueline Holanda de; Alves, Ana Paula Negreiros Nunes

doi:10.1007/s00520-022-07159-3

Cited by 3 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Creatinine levels exhibited significant differences among malignancies, with patients with solid tumors having the highest mean creatinine level. These variations imply differences in renal functions, tumor-related renal impairment, or nephrotoxic effects of chemotherapy [ 39 , 40 , 41 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Profiles, Laboratory Biomarkers, and Mortality in Cancer Patients with Lower Respiratory Tract Infections: A Prospective Cohort Study

Radwan,

Mourad,

Hamdy

et al. 2024

Medicina

View full text Add to dashboard Cite

Respiratory tract infections (RTIs) pose a substantial health burden worldwide, especially among immunocompromised groups like cancer patients. The aim of this prospective cohort study was to explore lower respiratory tract infections in cancer patients. We followed 107 cases with clinically or radiologically suspected lower respiratory tract infections until discharge or death, comprising 65 males and 42 females across diverse age groups. Clinical evaluations, including patient history, examination, and malignancy diagnosis, were conducted. Nasopharyngeal swabs (NPSs), sputum samples, and blood samples were collected within 24 h of symptom onset. Multiplex Real-Time PCR allowed for the simultaneous detection of viral, bacterial, and fungal infections, while conventional microbiological culture methods were used for bacterial and fungal analysis. SARS-CoV-2 infection was excluded in all of the enrolled patients using real-time RT-PCR. Hematological and biochemical analyses included hemoglobin, lymphocyte, neutrophil, and platelet counts, along with ALT, AST, creatinine, and CRP levels. Significant differences were noted in clinical presentations, management outcomes, and prognostic markers among patients with different hematological malignancies. Distinct clinical profiles were identified for leukemia, lymphoma, and solid tumors, with variations in age distribution and symptom prevalence. ICU admission rates varied significantly, with solid tumor patients exhibiting higher rates. The hematological and biochemical biomarkers differed across malignancies, with notable associations between lymphopenia, thrombocytopenia, and mortality following respiratory episodes. This study highlights the critical role of rapid pathogen detection and infection control measures in safeguarding vulnerable cancer patients from nosocomial transmission.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Profiles, Laboratory Biomarkers, and Mortality in Cancer Patients with Lower Respiratory Tract Infections: A Prospective Cohort Study

Radwan,

Mourad,

Hamdy

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…In the study by Travasso et al. [ 22 ], on 75 patients with hematological malignancies receiving antineoplastic treatment, the prevalence of renal disorders was 52.4% according to the CKD-EPI equation. After treatment of chronic myeloid leukemia with imatinib, CKD developed in 16% [ 23 ], whereas in other studies, CKD was diagnosed after therapy with tyrosine kinase inhibitors (imatinib, dasatinib, and nilotinib) in 22%, 5%, and 4% respectively and in 14% in the whole population [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

The prevalence of anemia in people with chronic kidney disease after hematopoietic stem cell transplantation

Kępska-Dzilińska,

Karakulska-Prystupiuk,

Kaszyńska

et al. 2023

Renal Failure

View full text Add to dashboard Cite

The hematopoietic stem cell transplantation (HSCT) is performed for various hematological diseases. Chronic kidney disease (CKD) occurs relatively often after HSCT. Anemia after HSCT may be due to CKD and/or other reasons. The aim of this study is to assess the prevalence of anemia and its possible relationship to the presence of CKD in patients at least 3 months after HSCT. The study included 156 patients who underwent allogeneic HSCT treatment in our center in the years 1998 to 2021 due to different hematologic pathologies (acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma, and others). Anemia was diagnosed in 13% of women and 35% of men. Anemia was most common in people after HSCT due to a history of acute myeloid leukemia (55% women, 30% men). In 56% of women and 17% of men, anemia was associated with chronic kidney disease. In patients with anemia, age was related to the eGFR (r = –0.39, p < 0.001), in patients without anemia age was negatively related to eGFR (r = –0.56, p < 0.001), and hemoglobin was positively related to platelet count ( r = 0.62, p < 0.001). Concluding, anemia, was relatively common in CKD after HSCT. In CKD, in particular with coexistent anemia, nephrology referral is to be taken into account to optimize therapy, including nephroprotection.

show abstract

How to manage the dose of drugs in cancer patients with acute kidney injury, practical recommendations

Janus,

Desplanques

2023

Int J Clin Pharm

View full text Add to dashboard Cite

Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment

Cited by 3 publications

References 42 publications

Clinical Profiles, Laboratory Biomarkers, and Mortality in Cancer Patients with Lower Respiratory Tract Infections: A Prospective Cohort Study

Clinical Profiles, Laboratory Biomarkers, and Mortality in Cancer Patients with Lower Respiratory Tract Infections: A Prospective Cohort Study

The prevalence of anemia in people with chronic kidney disease after hematopoietic stem cell transplantation

How to manage the dose of drugs in cancer patients with acute kidney injury, practical recommendations

Contact Info

Product

Resources

About